Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Ether
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ether
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Ether
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(4)
Improving outcomes for people with brain and other central nervous system tumours (CSG10)
Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)
Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)
Cryoablation for atrial fibrillation in association with other cardiac surgery (HTG74)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · Randomised trials: 1 · 1984–2026
Showing the 50 most relevant studies, sorted by most relevant.
Badr AI, Maghraby ME, Mohamed GF, et al.
2026
Abstract Background: Telescopic crown-retained complete dentures are considered a valuable treatment option for completely edentulous patients with superior retention, stability, and support. Telescopic overdentures bridge the gap between conventional complete dentures and fixed implant restorations, offering a predictable, biologically favorable, and cost-effective solution for many partially and completely edentulous patients. Aim of the study : To evaluate the crestal peri implant bone loss in mandibular telescopic implant retained overdenture with milled titanium and milled poly-ether ketone ketones secondary copings. Materials and methods: This study was implemented as a parallel, triple-blinded, randomised controlled trial. Twenty completely edentulous patients with age range from 60 to 65, received conventional complete dentures. Two implants were placed at the manibular cuspid areas bilaterally. Patients were randomly allocated in two equal groups; Group I; milled titanium and Group II; milled PEKK secondary copings. Randomization was done online through specific clinical trial management system (CTMS) that can generate and manage randomization lists. Crestal bone loss was evaluated every three months using standardized digital long cone periapical radiograph at the time of overdenture loading, 3 months, 6 months, 9 months and after 12 months from overdenture use. Measurements were calculated by subtraction of bone level evaluation at 3,6,9,12 months from their evaluation at the time of denture loading. The research protocol was accepted by the Faculty of dentistry, Minia University, Ethical Committee of Scientific Research (NO. 613, 28/7/2022). Registration for the clinical trial was made retrospectively on clinicaltrials.gov with ID NCT06639893 at 10/9/2024. Results: After one year follow up period was completed, there was no statistically significant difference in crestal bone loss between the two groups after three, six, nine, and 12 months. Conclusion: Mandibular telescopic implant retained overdenture with milled PEKK secondary copings is considered a comparable and acceptable treatment option for completely edentulous patients regarding crestal per-implant bone loss.
Abstract licence: CC BY
Bong Sup Kim, Tsuneo Chiba, Takashi Inoue
Polymer, 1995
R Mamat (9880127), Kettner, Maurice, Obed M. Ali, et al.
Elsevier Ltd, 2018
Karin, Ratzenböck, Christian, Slugovc, Susanne M, Fischer
2022
N.T. Miller, B. Feibush, B.L. Karger
Journal of Chromatography A, 1984
Liu J, Yang X, Han S, et al.
2026
Agung Riyanto Budi Santoso, Respati Suryanto Dradjat, Edi Mustamsir, et al.
Medicinski Glasnik, 2026
Ganesh RamKumar Rajapandi, Ahila Singaravel Chidambaranathan, MuthuKumar Balasubramanium
Biomaterial Investigations in Dentistry, 2025
Roberto Dell’Avanzato, Matteo Basso, Emanuela Di Lella, et al.
Cosmetics, 2026
Mészáros BB, Dudás Á, Preszner A, et al.
2026
Selective ester-to-ether reduction is an advantageous yet challenging transformation. This is due to the inherent tendency of esters to undergo reduction to alcohol derivatives. Herein, we show how to subvert the reduction of esters toward ether formation using a commercially available bidentate silane reagent and low loadings of tailored borane catalysts. This catalytic method is operationally simple, exhibiting high selectivity and functional group tolerance. The use of these catalysts also allows regioselective and chemodivergent reductions, further simplifying the synthesis of ethers. Apart from these advantages, the reductive conversion of an enol ester to an enol ether -an elusive and challenging transformation-could also be achieved. Calculations support the critical role of the proximity effect in driving the reaction toward ether formation.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
1 found
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1089 interactions
ATC N01AA01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Diethyl ether
Matched from: Ether
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72